Mutations in the gyrA, parC, and mexR genes provide functional insights into the fluoroquinolone-resistant Pseudomonas aeruginosa isolated in Vietnam
Authors:
Open Access
- 1 February 2018
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 11, 275-282
Abstract
Introduction: Pseudomonas aeruginosa has many mechanisms of resistance to fluoroquinolones. The main mechanism is to change the effect of two enzymes that open the DNA helix – the enzyme DNA gyrase (gyrA) and the topoisomerase IV (parC). In addition, mutations that render the MexAB-oprM pump (mexR) dysfunctional, leading to its overexpression, also enhance resistance to fluoroquinolones. In this study, we aim to detect point mutations of gyrA, parC, and mexR genes that are predicted to be associated with fluoroquinolone resistance in 141 fluoroquinolone-resistant clinical isolates of P. aeruginosa isolated in Vietnam during 2013–2016. Methods: We tested minimum inhibitory concentrations (MICs) of fluoroquinolone antibiotics in 141 clinical isolates of P. aeruginosa using the VITEK 2 Compact System, followed by PCR assay, to detect and clone the fluoroquinolone resistance-determining region (FRDR) of gyrA, parC, and mexR. Point mutations were analyzed through Sanger sequencing, and the correlation between genetic mutations and phenotypic resistance of 141 clinical isolates was undertaken. Results: Fluoroquinolone-resistant substitution mutations such as Ile for Thr83 and Met for Thr133 in gyrA, Leu for Ser87 in parC, and Val for Glu126 in the repressor of mexR were mainly detected. Comparative analytical data indicated that amino acid alterations within the gyrA and parC genes are highly associated with resistance to ciprofloxacin (CIP) and levofloxacin (LEV) in the isolates, whereas alterations in the efflux regulatory mexR gene are not highly consistent with resistance in these isolates. Moreover, fluoroquinolone-resistant clinical isolates of P. aeruginosa were mainly isolated from pus and sputum specimens. Conclusion: In clinical isolates of P. aeruginosa, a high correlation was observed between MICs of CIP and LEV and alterations in gyrA and parC genes. However, mutations occurring in mexR did not highly correlate with the antibiotic resistance of the bacterium.Keywords
This publication has 22 references indexed in Scilit:
- Fluoroquinolone use and fluoroquinolone-resistant Pseudomonas aeruginosa is declining in US academic medical centre hospitalsJournal of Antimicrobial Chemotherapy, 2012
- Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin useInternational Journal of Antimicrobial Agents, 2010
- Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosaInternational Journal of Antimicrobial Agents, 2009
- Update on the treatment of Pseudomonas aeruginosa pneumoniaJournal of Antimicrobial Chemotherapy, 2009
- Mechanism of action of and resistance to quinolonesMicrobial Biotechnology, 2008
- Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millenniumClinical Microbiology and Infection, 2007
- Pathogen–Host Interactions in Pseudomonas aeruginosa PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosaInternational Journal of Antimicrobial Agents, 2005
- Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protectionJournal of Antimicrobial Chemotherapy, 2003
- Resistance Mechanisms inPseudomonas aeruginosaand Other Nonfermentative Gram‐Negative BacteriaClinical Infectious Diseases, 1998